Vaccine
Moderna (mRNA-1273)
Developer
Moderna (USA)
Producer
Moderna (USA)
Стадия
Moderna and the National Institute of Allergy and Infectious Diseases began Phase III trials in the United States on July 27. 30,000 volunteers were divided into two groups: one group received two doses of 100 mcg of mRNA-1273, while the other received a placebo: 0.9% sodium chloride. By August 7th, more than 4,500 volunteers had taken part.
On November 16, 2020, Moderna released preliminary data from Phase III clinical trials that indicated 94% effectiveness in preventing COVID-19 infection. Side effects included flu-like symptoms, such as injection site pain, fatigue, muscle pain, and headache. Moderna’s results were not final: since trials will continue through the end of 2022, these results had not yet been reviewed or published in medical journals. On November 15, 2020, the U.S. National Institutes of Health confirmed that trials showed generally positive results.
Key information
What’s in the vaccine?
Moderna is a modified nucleoside bond between an RNA messenger (modRNA) called mRNA-1273, which induces immunity to SARS-CoV-2 by coding a stable spike protein on the surface of SARS-CoV-2 particles.
